<SEC-DOCUMENT>0000950170-25-103975.txt : 20250806
<SEC-HEADER>0000950170-25-103975.hdr.sgml : 20250806
<ACCEPTANCE-DATETIME>20250806160327
ACCESSION NUMBER:		0000950170-25-103975
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		12
CONFORMED PERIOD OF REPORT:	20250806
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250806
DATE AS OF CHANGE:		20250806

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Eledon Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001404281
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36620
		FILM NUMBER:		251189421

	BUSINESS ADDRESS:	
		STREET 1:		19800 MACARTHUR BLVD.
		STREET 2:		SUITE 250
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92612
		BUSINESS PHONE:		949-238-8090

	MAIL ADDRESS:	
		STREET 1:		19800 MACARTHUR BLVD.
		STREET 2:		SUITE 250
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92612

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Novus Therapeutics, Inc.
		DATE OF NAME CHANGE:	20170511

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tokai Pharmaceuticals Inc
		DATE OF NAME CHANGE:	20070622
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>eldn-20250806.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-08-06T14:55:57.8901+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:eldn="http://www.eledon.com/20250806" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_5ec0ef4e-0516-4dab-aa73-5e9c894bfd03" name="dei:EntityCentralIndexKey" contextRef="C_502a57ac-65d1-44e4-b1ec-0d018b37d327">0001404281</ix:nonNumeric><ix:nonNumeric id="F_841276ef-13f2-48a3-9a50-b6d065e32840" name="dei:AmendmentFlag" contextRef="C_502a57ac-65d1-44e4-b1ec-0d018b37d327">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="eldn-20250806.xsd"/></ix:references><ix:resources><xbrli:context id="C_502a57ac-65d1-44e4-b1ec-0d018b37d327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-06</xbrli:startDate><xbrli:endDate>2025-08-06</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="border-top:2.25pt double #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES<br/>SECURITIES AND EXCHANGE COMMISSION<br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><h2 style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_81894906-6b70-4329-a58f-a72c9467864a" contextRef="C_502a57ac-65d1-44e4-b1ec-0d018b37d327" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8-K</span></ix:nonNumeric></span></h2><p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CURRENT REPORT</span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.398%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span><ix:nonNumeric id="F_2505cf70-d722-4473-81a4-a1d3e427db33" contextRef="C_502a57ac-65d1-44e4-b1ec-0d018b37d327" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">August 06, 2025</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="margin-left:40%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0be36927-077a-4904-97e7-c071dc3dfd6d" contextRef="C_502a57ac-65d1-44e4-b1ec-0d018b37d327" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Eledon Pharmaceuticals, Inc.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p><p style="margin-left:40%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:20%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:20%;box-sizing:content-box;"/>
     <td style="width:18%;box-sizing:content-box;"/>
     <td style="width:41%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_47304ba4-b9c8-40d8-8a91-8c54beadc4d3" contextRef="C_502a57ac-65d1-44e4-b1ec-0d018b37d327" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_fe0a2b56-3c7a-4e46-b91a-043aed291c7a" contextRef="C_502a57ac-65d1-44e4-b1ec-0d018b37d327" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">001-36620</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_820d975b-3a16-4db3-b294-fec4f88c9c8e" contextRef="C_502a57ac-65d1-44e4-b1ec-0d018b37d327" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">20-1000967</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or Other Jurisdiction<br/>of Incorporation)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Commission File Number)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(IRS Employer<br/>Identification No.)</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_517366ec-31ce-4923-b15c-acc9c96ca850" contextRef="C_502a57ac-65d1-44e4-b1ec-0d018b37d327" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">19800 MacArthur Blvd.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_e783693c-fb81-4bc4-bc26-68c47e0e9956" contextRef="C_502a57ac-65d1-44e4-b1ec-0d018b37d327" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Suite 250</span></ix:nonNumeric></span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_66e10d00-6ebd-44e5-a9bf-e30d6d45796f" contextRef="C_502a57ac-65d1-44e4-b1ec-0d018b37d327" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Irvine</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_74922468-c6cf-40d9-a3c3-cb79ae39f180" contextRef="C_502a57ac-65d1-44e4-b1ec-0d018b37d327" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">California</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_86d36c5c-c22e-4443-b15f-9756c50e90c4" contextRef="C_502a57ac-65d1-44e4-b1ec-0d018b37d327" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">92612</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="3" style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.125in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.398%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Registrant&#8217;s Telephone Number, Including Area Code:</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_9f589433-a284-4d99-b932-5c082f8dab7f" contextRef="C_502a57ac-65d1-44e4-b1ec-0d018b37d327" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">949</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_8f8d79e0-dc68-44cd-b331-d74316323a43" contextRef="C_502a57ac-65d1-44e4-b1ec-0d018b37d327" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">238-8090</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:100%;box-sizing:content-box;"/>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.125in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p><p style="margin-left:40%;font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:3pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e68fa96c-ebc7-4457-a152-ecb22ed2ca85" contextRef="C_502a57ac-65d1-44e4-b1ec-0d018b37d327" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_794c8f38-38be-4b99-a0f1-c4b7454c87ee" contextRef="C_502a57ac-65d1-44e4-b1ec-0d018b37d327" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cc2c8223-9a10-4d95-976f-075a9d774821" contextRef="C_502a57ac-65d1-44e4-b1ec-0d018b37d327" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b1d3ff02-5c34-4338-9a1f-8df624cb01c2" contextRef="C_502a57ac-65d1-44e4-b1ec-0d018b37d327" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:9pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:38%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:15%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:45%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>Title of each class</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading<br/>Symbol(s)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>Name of each exchange on which registered</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_64409c67-b537-4307-8205-db213581b432" contextRef="C_502a57ac-65d1-44e4-b1ec-0d018b37d327" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common Stock, $0.001 par value</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_6106bb60-2d1f-47db-98f2-903a8872effe" contextRef="C_502a57ac-65d1-44e4-b1ec-0d018b37d327" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ELDN</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_6770fcad-ca8f-4807-9b7c-4b29c4b9f2f6" contextRef="C_502a57ac-65d1-44e4-b1ec-0d018b37d327" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nasdaq Global Market</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging growth company </span><span style="font-size:10pt;"><ix:nonNumeric id="F_db236f29-a750-4416-96a2-8d706d182245" contextRef="C_502a57ac-65d1-44e4-b1ec-0d018b37d327" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><h2 style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 7.01 Regulation FD Disclosure.</span></h2><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 6, 2025, Eledon Pharmaceuticals Inc. (the &#8220;Company&#8221; or &#8220;Eledon&#8221;) issued a press release announcing updated data from the Company's ongoing Phase 1b open-label trial evaluating tegoprubart for the prevention of organ rejection in kidney transplant patients. Results were presented at the World Transplant Congress taking place in San Francisco, CA. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Also, on August 6, 2025 and as previously disclosed, the Company is hosting a conference call to discuss the updated Phase 1b clinical data. A copy of the presentation for the conference call will be posted on the Company&#8217;s website at https://ir.eledon.com/investor-relations prior to the conference call.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be, or be deemed, incorporated by reference in any filings under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), unless the Company specifically states that the information is to be considered &#8220;filed&#8221; under the Exchange Act or incorporates it by reference into a filing under the Securities Act or the Exchange Act.</span></p><h2 style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></h2><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d) Exhibits</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:13%;box-sizing:content-box;"/>
     <td style="width:87%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit No.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:13%;box-sizing:content-box;"/>
     <td style="width:87%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.1</span></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">P</span><a href="eldn-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">ress Release Issued on </span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid #0000ff;font-kerning:none;min-width:fit-content;">August 6, 2025</span></a></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
     <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:2;min-height:0.5in;position:relative;"></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:6%;box-sizing:content-box;"/>
     <td style="width:44%;box-sizing:content-box;"/>
     <td style="width:4%;box-sizing:content-box;"/>
     <td style="width:46%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:4.3pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Eledon Pharmaceuticals, Inc.</span></p></td>
    </tr>
    <tr style="white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">August 6, 2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ David-Alexandre C. Gros, M.D</span></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name: David-Alexandre C. Gros, M.D.<br/>Title: Chief Executive Officer<br/></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>eldn-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><img src="img20068692_0.jpg" alt="img20068692_0.jpg" style="width:186px;height:47px;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Data from patients who remained on tegoprubart for a year showed overall mean 12-month eGFR of approximately 68 mL/min/1.73 m&sup2; post-transplant</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Preliminary iBox data, a key biomarker of kidney function and immunologic response, supports that tegoprubart may improve 5-year graft survival vs. current standard of care</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Tegoprubart continues to be well tolerated with no cases of death, graft loss, drug related tremor, or new-onset diabetes</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-style:italic;font-kerning:none;min-width:fit-content;">Conference call to be held today at 4:30 p.m. ET</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">IRVINE, Calif., August 06, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (&#x201c;Eledon&#x201d;) (NASDAQ: ELDN) today announced updated data from the Company&#x2019;s ongoing open-label Phase 1b trial evaluating tegoprubart for the prevention of organ rejection in kidney transplant patients. Results from the oral presentation, titled &#x201c;Tegoprubart, an Anti-CD40L Antibody, for the Prevention of Rejection in Kidney Transplantation: An Ongoing Phase 1b Study,&#x201d; were presented today at the World Transplant Congress (WTC) taking place in San Francisco, CA.</font></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#x201c;The data presented today at WTC further reinforce our belief that tegoprubart has the potential to not only provide better protection and long-term preservation of kidney function following transplantation, but also to offer a safer alternative to traditional immunosuppressive therapies by minimizing harmful side effects,&#x201d; said David-Alexandre C. Gros, M.D., Chief Executive Officer of Eledon. &#x201c;The continued strength of the Phase 1b data through 12 months of treatment is highly encouraging as we look ahead to topline results from our Phase 2 BESTOW trial, expected in November, which compares tegoprubart to tacrolimus, the current standard of care.&#x201d;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">As of the July 2025 cutoff date, 32 patients undergoing kidney transplantation have been enrolled in the Phase 1b study. Updated data showed that kidney function, as assessed by estimated glomerular filtration rate (eGFR), stabilized after the first month post-transplant and remained in the range of approximately 68 mL/min/1.73 m</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> through 12 months for patients (n = 12) who remained on tegoprubart</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Kidney function in the intention-to-treat population (n=15) was approximately 63 mL/min/1.73 m</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> at 12 months. Data from historical studies using the standard of care, calcineurin inhibitor-based immunosuppression therapy, typically report aggregate mean estimated glomerular filtration rates (eGFRs) of approximately 53 mL/min/1.73 m</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> during the first year after kidney transplant.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">In addition, preliminary abbreviated iBox data was presented suggesting that tegoprubart may improve 5-year graft survival. Abbreviated iBox, a composite biomarker panel developed by the Paris Transplant Group, incorporates kidney function (eGFR, proteinuria) and immunologic response (donor-specific antibodies) parameters into a single prognostic score. Based on data collected to date, abbreviated iBox scores were -3.75 in the intention-to-treat population and -4.11 in the on-treatment population, which compare favorably to a -2.98 historical mean for calcineurin inhibitors. A difference in abbreviated iBox score of -0.40 at 12 months is considered predictive of a 4-5% difference in 5-year graft survival suggesting that tegoprubart may have a predicted 5-year allograft survival rate of over 96%.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Mean tegoprubart treatment exposure to date was 233 days. Tegoprubart continues to be well-tolerated with no cases of death, graft loss, drug related tremor, or new-onset diabetes, a side effect associated with standard of care immunosuppression therapy.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">There were six (18.8%) rejection episodes, and 75% of patients who experienced a rejection had received low-dose rabbit antithymocyte globulin (rATG) induction. All rejection episodes were successfully treated. Of the patients who experienced a rejection episode and completed a year in the study, three who remained on tegoprubart had a mean eGFR of approximately 73 mL/min/1.73 m</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">2</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">  at 12 months, indicating full recovery of kidney function, while the two patients who switched to standard of care tacrolimus had a mean eGFR of approximately 34 mL/min/1.73 m&sup2; at 12 months.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">All 32 patients received rATG induction therapy and a maintenance regimen consisting of tegoprubart, mycophenolate mofetil, and corticosteroids.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:0.796%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.359743558727471%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cohort 1 has completed enrollment and evaluated tegoprubart at a dose of 20 mg/kg with rATG induction up to 6 mg/kg. </font></div></div><div class="item-list-element-wrapper" style="margin-left:0.796%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.359743558727471%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Cohort 2 is currently enrolling and is evaluating a lower tegoprubart dose of 10 mg/kg, with a required rATG dose of 4.5 mg/kg. </font></div></div><div class="item-list-element-wrapper" style="margin-left:0.796%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.359743558727471%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">The primary endpoint of the study is safety and pharmacokinetics. Secondary and exploratory endpoints include patient and graft survival, biopsy-proven acute rejection, kidney function as measured by estimated by eGFR, and abbreviated iBox score.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Eledon is also conducting a Phase 2 trial (BESTOW; NCT05983770) and a long-term safety and efficacy extension study (NCT06126380) to evaluate tegoprubart for the prevention of organ rejection in patients receiving a kidney transplant. Topline results from the Phase 2 BESTOW trial are anticipated in November 2025.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Full details of the WTC oral presentation are below:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Title:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> Tegoprubart, an Anti-CD40L Antibody, for the Prevention of Rejection in Kidney Transplantation: An Ongoing Phase 1b Study<br></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Session:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> Oral Presentation, Kidney Novel Immunosuppressant Strategies<br></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Presenter:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> John Gill, MD, MS, University of British Columbia, Vancouver, Canada<br></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Session Date and Time:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> Wednesday, August 6, 2025: 10:00 a.m. &#x2013; 11:15 a.m. PT</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Conference Call</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Eledon will hold a conference call today, August 6, 2025 at 4:30 p.m. Eastern Time to discuss the updated Phase 1b trial results. To join the conference call, please dial 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers. The conference ID is 34575. Registration for the live webcast can be found here and available on the &#x201c;Events&#x201d; section of Eledon&#x2019;s website at www.eledon.com. The webcast will be archived on the website following the completion of the call.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">About Eledon Pharmaceuticals and tegoprubart</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company&#x2019;s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company&#x2019;s website at www.eledon.com.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">About iBox</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">iBox is a composite biomarker panel developed by the Paris Transplant Group to predict long-term kidney graft survival. It combines kidney function (eGFR, proteinuria), immunologic response (donor-specific antibodies), and histopathology (Banff scores) into a single prognostic score. Validated across four independent cohorts, including two Phase 3 trials (BMS BENEFIT and BENEFIT-EXT), iBox has demonstrated strong predictive accuracy (C-statistic &gt;0.8) for 5-year graft loss and outperforms traditional markers like biopsy-proven acute rejection. Both full and abbreviated iBox models have been qualified by the European Medicines Agency (EMA) and accepted by the U.S. FDA into the Biomarker Qualification Program. The iBox Composite Biomarker Panel is under review by the FDA as a Reasonably Likely Surrogate Endpoint (RLSE) for use as a co-primary endpoint in Phase 2/3 trials, supporting potential accelerated approval of novel immunosuppressive therapies. This makes iBox the first transplant-specific endpoint formally recognized under FDA&#x2019;s biomarker qualification framework.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Forward-Looking Statements</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">This press release contains forward-looking statements that involve substantial risks and uncertainties. Any statements about the company&#x2019;s future expectations, plans and prospects, including statements about ongoing clinical trials, the development of product candidates, expected timing for initiation of future clinical trials, expected timing for receipt of data from</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:2;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;margin-left:0;margin-right:0;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">clinical trials, expected or future results of tegoprubart trials and its ability to prevent rejection in connection with kidney transplantation, as well as other statements containing the words &#x201c;believes,&#x201d; &#x201c;anticipates,&#x201d; &#x201c;plans,&#x201d; &#x201c;expects,&#x201d; &#x201c;estimates,&#x201d; &#x201c;intends,&#x201d; &#x201c;predicts,&#x201d; &#x201c;projects,&#x201d; &#x201c;targets,&#x201d; &#x201c;looks forward,&#x201d; &#x201c;could,&#x201d; &#x201c;may,&#x201d; and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently uncertain and are subject to numerous risks and uncertainties, including: risks relating to the safety and efficacy of our drug candidates; risks relating to clinical development timelines, including interactions with regulators and clinical sites, as well as patient enrollment; and risks relating to costs of clinical trials and the sufficiency of the company&#x2019;s capital resources to fund planned clinical trials. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors. These risks and uncertainties, as well as other risks and uncertainties that could cause the company&#x2019;s actual results to differ significantly from the forward-looking statements contained herein, are discussed in our quarterly 10-Q, annual 10-K, and other filings with the U.S. Securities and Exchange Commission, which can be found at </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">www.sec.gov</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">. Any forward-looking statements contained in this press release speak only as of the date hereof and not of any future date, and the company expressly disclaims any intent to update any forward-looking statements, whether as a result of new information, future events or otherwise.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Investor Contact:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Stephen Jasper<br>Gilmartin Group<br>(858) 525 2047<br>stephen@gilmartinir.com</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Media Contact:</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Jenna Urban<br>CG Life<br>(212) 253 8881</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">jurban@cglife.com</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Source: Eledon Pharmaceuticals</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img20068692_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img20068692_0.jpg
M_]C_X  02D9)1@ ! @$ 2 !(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !1 3X# 2(  A$! Q$!_\0
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MO#=I?Z?/KFK:WXBTC3[1]2TNQ2XGU/5=-L;O] J_B/\ ^#Q[_G'/_P!W=_\
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MOB#P[K/A6ZUC77M?$?BJ_P!<6STC7;U]+T^WGT:&#4Q!>7DFH0Q"S(!]L_\
M!<3]LKXW?L)_L#>+?CQ^SYJ/A_1_B5#\0/ '@W3]7\2>'[7Q/9Z78>*]0N[7
M4+ZTTC4'_LV;4X(X$:R?4K:_L8W+&XL+E2%'YX_\&['_  6!_:'_ ."@][\;
M_@9^U7J7AWQ?\3/A9X9\-_$+PA\1M$\,Z+X/U/Q5X4U#59?#GBBQ\5:#X7M-
M)\*I?:%J]SX:GTN_\/Z%I$=U;ZY?6]]:![&UGN/9/^#HK_E%)XN_[+=\&?\
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M_P#R>S^TM_V:S<?^K:^&]?OA_P '17_**3Q=_P!EN^#/_IYU&OP/_P"#0_\
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MC1]*TO6?''Q2:PN(9;>YUJRBU_1?#/@:_9_^)%>0^,M16U.JIX>U/2P#\./
M?_!#[_@L%^T1HX^*&E?LB_$_4XO$?E7[ZQ\6_'?PU^&/BW5Q<1 P7]UHOQK^
M(?@WQG<QSP1QM%>7.ELDD!@=)6BDA+</H7Q9_P""JW_!'?XLZ1H5QK7Q_P#V
M8/$5M)]OM?A]XR?4KWX3^/--L+BW%VT/AC5)=7^%_P 0M#5I$L9]8T)=4_LY
M[B2.PU;3[]A(G^LO7QM^WE^Q'\'O^"@/[-WCG]GGXP:/9SV^N6%U?>!?&'V*
M&XU_X9?$*VLKF/PSX\\,7+@3VM_I-U.8]0M89H8-?T&YU7PYJ?G:7JMY#( ?
M!G_!&7_@LKX#_P""HOP[UGPYXHT?1_AI^U1\,-*L;[XE_#G3+N9O#_BC0KB9
M+"/XE?#-=2N;G59/"TNI/#8Z]H5[<ZEJ?@;5;_2].U+5=5LM8T+6M6]>_P""
MXWC+Q?\ #_\ X)3?MC>+? ?BOQ)X)\5Z5X'\)II?B;PCKFJ>&_$.FIJ7Q2\!
MZ3J*V&M:-=66I6:W^EWU[IMZMO<QBZT^\NK.<26]Q-&_^<_^P)\:?B#_ ,$[
M_P#@I;\'O%6J37FBZO\ "/X^GX2_&71K&XN5CU#PE=>*9OAM\6_#L\)^S+J"
MQZ7-K%QI<.H6YA@U[3='U0V\=W86[1?Z'G_!?3_E$-^VK_V)/@;_ -7%\.:
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M(QDYUF4445^9']%A7\1__!X]_P XY_\ N[O_ -]@K^W"OXC_ /@\>_YQS_\
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M28^*'ANW\06_[6WACP-<O% U_P"&/B?X9\;>!_$FD7$ZNWV*YAU/PZ=)U.6
M(1/=>&M7UW2XV9%&H,SJ#^9G_!1O_@Z'_9F^&GP]\2> OV"+^^^.WQJU_2KW
M2M*^*E[X9UKPW\)_AA=74+V[>(5M_&.E:3KOQ \1Z69!<:)HUEH4?@Z>[$=[
MJOB2]M;.7P_JX!ZO_P $QO\ @W%T_P#X)U?M;>$OVJ;W]L"\^-%SX,\,>-]#
MTGP1:_ >#X9P3:AXT\/77A>34M1\02_&'XB23V>GZ5J6INFEVVC6<]SJ$EC<
M-JT-M9W%E?\ \LW_  <G^&-4T#_@L)^TOJNH1>7:>-O#OP$\3Z&^UQYVEVGP
M#^&_@R:7+*JMC6O".KP[HRZ#RMI82*Z+_1%_P:N_M)?MM?M!>$_VI4^/_P 2
M_B+\7_@AX-U3P-;?#[QC\5M?UGQAKVG?$C6?^$@O_&'ACPWXO\0SWVLZAH\.
M@KX?U76]"N=2NK#PW=7^@SZ3:Z>?$.I?;,+_ (.I/^"='C+XQ>!OAY^WC\(O
M#=YXDUSX(>%[WX>_';1]&LI[[6!\(UU*_P#$WAGQ]%:6L+22Z1\/-<U7Q3#X
MON )I[/1/%-GK<RV^A^&M8O+8 _=3_@CA\1O#OQ0_P""7'["WB#PQ+826.C?
MLZ?#SX<WZZ=Y(BA\1?"?2(_ACXHBN$@FG"7_ /PD/A+4I=0\QDFENY)9Y88'
MF,2?I;7^9_\ \$1_^"YFK_\ !-237/@A\;?#WB3XD_LI>,M=F\3Q67A<V=WX
MZ^$OC*_CL;34_$'@^TU?4=-T[6/#&NVME"_B;P;/J.FA=3@C\2Z!>6VISZ_I
M_BG^N34/^#E#_@CY9^%I_$%O^TIXDU;5HM,6_C\#:?\  7X\Q^*;FZ,:N=%@
MN]4^'.F^"EU-68Q-+<^,+?1C(C%=6:(I(X!8_P"#DKQ)HNA_\$=_VH-,U74(
M+.^\8ZY\ O#?ANWE;;)JNM6O[0GPO\73Z?:C^.>/P[X5U_5&4=+;3;A^B5_*
MA_P:D_\ *3W7_P#LUKXK_P#J7_"VO%_^"PO_  5F^+?_  5PUN^L_A=\-?%/
M@C]D']F&!OB"-!O7CO\ 79[CQ#XET/X8:7\6_BY-IDT^A:-?7&I^-="\%^$_
M#FG76K0>&I_%VK6L6OZ[)KEW=6_M'_!J3_RD]U__ +-:^*__ *E_PMH _0?_
M (/#_!FN'4/V$?B%':M+X:2S^/O@R\O4!*6&N23_  JUO3;6Z8@*&U:PBU66
MQ"%RPT743*(PL/F_HQ_P:G?$CPOXK_X)JZYX"TR_@;Q1\*_V@_B%I_BC2&GA
M-];6WBW3?#7BOP]K!M%8SQ:5JL%[J&G6-U*BQW6H^'];AA9S8RA?TS_X*V?\
M$_M,_P""D7[%_CSX"0W>GZ/\2M)O+/XD_!'Q)J>]=.T7XJ^%K+4H-'MM6FB2
M26VT+Q7I&JZYX*UR\C@NY-*T[Q%-KEO87][I5I:R_P"=Q^P=^W+^U/\ \$4O
MVOO'":KX U6UO+.Z_P"%<_M(_LY^-Y[GP]'XGLM%NY;JP#7D4&H1:1XI\.RW
MD^K> _&]E9ZQ9'3M9OOLJZQX5\4ZA!J0!_J\4UV5%9W941%+.[D*JJH)9F8D
M!54 DDD  $DXK\$/A%_P<L_\$F?B1X0@\0^+?C=XK^".OIIG]H:MX$^)7PD^
M)E_KNG/$(UNK:VU3X:^&/'WA76Y4FDVVEOI.O7&IWT(,\>F1^7<1P?BM_P %
M;/\ @YK\&_%CX4^-/V;?^"?NG^,+:S^(.CW_ (6\>?M&>+=+F\(WT'A?4U-K
MK&D?"?PO<RMK]K=>(=*DFTN\\8^*[70-5T6RN[^/0O#L>K/IOB;2P#^<'XWW
MMI^TG_P59^+VI?".>/Q)8_'S_@H1X_O?AC=1$F+7[3XI_M'ZM/X+GC-L+HF/
M5(==TV1# +@E9QY0F.T-_HK?\%]/^40W[:O_ &)/@;_U<7PYK^87_@V2_P""
M5?C/XE_&G0/^"A?QF\+7.C_!CX22ZC)\ [77;-X6^*/Q3:.]T8^,]'MI\/<>
M$?AANOI[?6VB2UO_ (@_V1%HEU=S^$O$L-E_3U_P7T_Y1#?MJ_\ 8D^!O_5Q
M?#F@#^,?_@UU_P"4K?A'_LB/QF_],VG5_I=5_FB_\&NO_*5OPC_V1'XS?^F;
M3J_TNJ /SL_X*Y?\HPOV]/\ LUKXP_\ J(:E7^1E7^N;_P %<O\ E&%^WI_V
M:U\8?_40U*O\C*@#_2%_X*&_\$\M9^$FI^(_CE\'[&?6/A1J5[<:SXJ\.6ZO
M/JGPYN[^XDGO;J&%$+7G@@W$F^&Z0M<^'DE^S:@C:=;KJA@_X)^?\%%]2^"]
MSHGP:^-6HSZG\'YI5L/#OBBX\ZZU3X:R3R*L$$S@R37_ ((61F$UD(Y+S0$D
M^T:8TEA;G2C_ $N7%O;W=O/:7<$-U:W4,MO<VUQ$DUO<6\R-'-!/#(K1RPS1
MLT<L4BLDB,R.I4D'^=#_ (*$?\$WI_AX^J?&O]GS09[KX?E)]0\;_#[34EN;
MGP-Y43SW?B#P] 3)/<^$&1'FU+3D,EQX9DW7%LLGAYWC\/\ ]>>'GB5P_P")
M61T_"_Q6]G4K58PH</\ $=65.E6>(ITW2PD*N+G=87.:*ER83&R3HYE!RP>.
MC.M4DLP_RJ\>/H\\<_1YXSK_ $D/HR.OA\'AJE;&\=>'^&IUL3A(8"M7CB<S
MJ87*Z+B\QX3Q;C[7-,F@XXKA^K"&:Y-4HX3#PED?]%.GZA8:M8V>J:5?6>IZ
M9J-K!>Z?J.GW,-[8WUE=1K-;7=G=VSR6]U:W$+I+!<02/%-&ZR1NRL"?SV_X
M*J?\F6?$3_L/_#W_ -3;1:_(7]@7_@H5JW[.=W:_##XHS:CK_P $]2O5%C<)
MYM[JOPTO+VY#76HZ5"/,GO?#$SRRW>L^'[<-/!.9-5T.,WTM_I^L_K9_P4_U
M33M;_8:\9ZUI%[;:EI.KZC\,M4TO4;.5)[2_TZ_\7:#=V5[:SQDI-;75M+%/
M!*A*212*ZDA@:^%I>&>>>&OC#P)@,QB\5EF*XPR.>3YS2IN&'S&A#-<&Y1E&
M\OJ^-H*<(XK"RDW3DU.E.KAYTJT_VG$_2*X-^D-]$_QJSO(9K+>(LL\*>,:7
M%G"6(K*KC\AQU;AO-%"=.IR4OK^48V5&K/+<SI4X1KTX2HXBEA<=1Q.$H_GQ
M_P $4O\ DJ/QL_[$'P__ .I$]>"?\%:_^3PM:_[$+P-_Z07->]_\$4O^2H_&
MS_L0?#__ *D3UX)_P5K_ .3PM:_[$+P-_P"D%S7]!95_RE)Q)_V1=#_U#R _
MA7B3_E6MX?\ _9WL;_ZM>-C^@O\ 8P_Y--_9W_[)'X)_],MK7TU7S+^QA_R:
M;^SO_P!DC\$_^F6UKZ:K^&^+?^2JXF_[*#.?_5CB3_9OPM_Y-EX<_P#9"<(_
M^L_EX4445\^?=A1110 5^<?_  4A_P""7W[-_P#P4_\ AMX0\!_'J3QEX=UC
MX<:UJ>N_#KXB_#O4]+TSQAX3N->MK&U\1Z9%_;VC>(=#U'P]XFCTG13KVEWV
MD/-/)HFE7%A?Z;=VB7-?HY7SU^U;^TQ\.?V.?V>/BG^TS\68/$EW\/OA'X?B
M\0>(;'P?IEKK'BG4EN]5T[0M,TO0=.O]2T;3KC4]4UG5M.T^U.IZQI.EP27(
MN-2U.PL8;B[B /YN?^(0_P#8G_Z.6_:E_P"__P )O_G<T?\ $(?^Q/\ ]'+?
MM2_]_P#X3?\ SN:_4>3_ (*^QZ;%-J/BS_@F/_P5O\&>&[")KK6O%.L_LBZ#
MJNDZ%IT6#=:IJ5GX+^+_ (K\2-I]E%NN;Z?3M U V=G%/=SQI;032I[#\7?^
M"GGP!\)_\$^O''_!1;X*WEM^T1\'O!FF:)J?]G>&-5F\*:O?&^\=>&_!6N:)
M?P^(-%DU/PKXK\-MX@>]O/#7B70]/U SVD-C=KIL&H1:E$ ?BO\ \0A_[$__
M $<M^U+_ -__ (3?_.YKZO\ V*/^#;?]C/\ 8K_:*\!?M+:%\3?CQ\4/&?PP
MNKS5O!.A^.]8\%6?A33_ !%<Z?=Z9!KVH6GA3P9H>JZI=:5!>S7&EVDFKP::
ME\(KB_L]02)(%_H<HH ^-_V]?V)OAA_P4&_9G\;?LR?%G5/$7A_P[XKNM#UK
M3?%'A.:SB\0>%_$_AC4H=5T+6K"/4;:\TZ]CCGBDL]1TZ]MFBO\ 2KV^M8IK
M*ZDM[^U^+/\ @EE_P12^ O\ P2S\2?%#QWX!^(WQ ^+'Q ^)^@Z5X1N_$7C:
MUT'2;7P]X1TW4?[9GT?0](T&V0>;K6KQ:?>:Q?ZC?7S2+HNDP:?;Z<L=^^H_
MLW10 5^/7_!0;_@AY^PQ_P %$=8O/B!\1?"FN?"[XWW=K';W'QJ^#UUI?ASQ
M5K[6D-O;Z>?'>DZCI6K^%_'7V2VM+73EU'6M'_X2B+1H(M(T_P 2Z=:6]FMK
M^PM% '\/7B?_ (,[M;75)&\&?MZZ5-HLFYX8O$_[/%W;:I:9=@MO)/I7QAN[
M34-L85FO%MM,WNS(+%%02/\ 5/[-_P#P:/\ [+7@/6=/UW]IG]H;XF?M!1V4
MEM=/X,\&>';'X(>#]1E259+C3=>O+?Q!X]\:ZAI4D6^V,OAWQ1X)U60XNXKR
MS)^RK_6Y10!YG\'_ (-?"G]G_P"'?AOX2_!/X?\ A;X8?#;PC:O:>'O!O@[2
M;;1]%T])II+J\N/L]LBM=:CJ5[-/J&KZM>R7.J:QJ5S=:EJEY=W]S/<2>CSP
M074$UM<PQ7%M<1207%O/&DT$\$R&.6&:*0-'+%+&S))&ZLCHQ5@5)%2T4 ?S
M'_MG_P#!K9^Q1^T9XLUKX@_ 3QKXK_9#\5>(+F:]U/PYX2\.Z5X\^#2WUPS2
MSWVC_#;4-3\+:KX;:XG=F?2?#GCO2O"MI$([?1_#NEQH0_P7X _X,\=/@\0Q
M7'Q2_;LO-3\*6]Y&9])\ ? :'0_$.K:>';S5B\1>(OBAXATWP]>&,((V?POX
MG@5Y&9D=80L_]LE% 'Y+Z3_P16_84\(_L/?&#]@_X?>!-7\%?#KXY:3H<'Q'
M^(=EJL6I?&#Q3XE\):YIOBKP;XQUWQAJME<QZE?^%?%.D6&M:-H']F6W@S3W
M%]9:=X;L;+5-0AG\<_X)??\ !"/]GS_@F)\6O&?QP\'_ !2^(_Q>^(WBCP-=
M?#G3+[QG8^'M%T?PMX8U76-&UW7O[.TG1+9GNM:U:^\.Z-"=5NK\BRTVWN[&
MUM$&HWDTG[ET4 %?G!^WM_P2C_8O_P""C>D6H_:%^',L/C_1]/\ [,\,?&?P
M!?1>$_BOX=L5DEEBTZ/Q +*_T[Q'HL$EQ=26OA[QKHWB;0K&>\N[W3M.L]0G
M:\'Z/U6O+RTTZTNM0U"ZMK&PL;:>\O;V\GBMK2SM+:)I[FZNKF=DAM[:WA1Y
MIYYG2**)&DD944D '\7GBS_@SK\(7FMW4_@;]OSQ)X=\..SFRTKQ9^S=IGC/
M6[=#-*R+=:_H_P ;? =C>,L!@B=HO#5B'FCEG"(DR6\'V]^R'_P:S?L+? +Q
M'I?C7X\>*_&_[6WB+1KN&\L/#OC"PL/ 7PC:YMI!/;7&J_#_ $"^U?5_$7E3
M(AFTKQ%XZU7PMJ4(>TU?PYJ%K++$_P#25X.\8^$OB'X4\.>._ ?B70O&?@KQ
MAHNG>(_"GBSPQJMEKGAWQ'H&KVL5]I>LZ)K&FS7%AJ>F:A9S17-G>VD\MO<0
MR))&[*P-<%\%_BU=?&'1/%VM77PI^+7PD'A7XF>//AS;:9\7_#%GX3U?Q?:^
M!]:DT:+XB^$]/M]8U:XO/AUXP,;WW@W7-232;S6].C;4H=+&EW&FW^H 'IVB
MZ+HWAO1]+\/>'=)TS0- T/3[32=%T/1;"UTO1](TNP@2UL--TO3+&*"RT_3[
M*VBCM[2SM((;>V@C2&&-(T51XG^U1^S=\/?VOOV>?BO^S5\5#K$7@/XN^%I_
M#&NW?AZ\AL->TLK=VFJ:5K6BW5U:WUG%JNAZWI^FZQ8"^L;[3Y;JQBBO[*\L
MWGMI??Z* /P<_P""9W_! G]G7_@FK\<M:_:$\+?%?XF_%[Q_<^#=7\#^&1XR
MM/#NAZ)X4TSQ#=:?/K>HP:?X?MEGU37;NUTV/2H;N]OET^TTZ\U,+I4EY<6M
MY8_O'17R?^U+^U3I7[+VJ?LL6&K^$+[Q5!^TY^UA\/?V5K2ZL-6ATR3P=JOQ
M'\'?$?Q+I/B^XMI["\&N6-IJ'@*WTB^TF.XTJ86VMR:M%?R/I0TO4@#V'XV?
M"'P7^T!\'OBC\#?B/:75]X"^+W@'Q9\./%]OI]R+'4F\/>,=$O=!U232[XQ3
M_8-5M[6^DN-,OQ#*UC?Q6]VD;M"%/\U_PC_X--?V%O!/B36M5^)?Q=^.OQAT
M*[TZ6RT3PS=W/A;P5'H]S)?VURFJW>JZ!I$]YJU]!9V[:?%&JZ;8%;R\N9;*
M24V8L_ZGZ* "D(# JP#*P(92 001@@@\$$<$'@BEHH _'SX[?\$A?AM\3/B0
M_C;X<^.IOA-HNNWYOO%7@ZV\,0:[I,,\K/+>W'@X)JVC+H,=](%/]D7$=_IU
MA/<3W&G"WL(;;1%]$_X*,^#]*^'G_!/74O &@M=-H?@:T^#G@_1FO95GO6TK
MPSK_ (9T73FNYU2)9KHV=E";B58XUDE+N$0':/T_KXO_ ."@7PJ\;?&7]E;X
MB>"/AYI+:_XLFN/"VL:?HD4L,-UJD6@^)]*U34+6Q:X>*&2]&GV]S/;6[R(U
MW)"+6#?<30QO^P<,^(O$F=\6^&F$XKXAGBLFX:XGR2IAJF8/"TH8.C',,)&K
MB<9CO9TZU?V5"FHRQ./KUG1HQD_:1BZCE_*'B-X!>'W!OA;](C,_##@*CEW%
MOB'X=<88?,,/D4<QQ-7-L7/(\SGALORG)OK&(PF!^LXRO*I#+\DP6$CBL54@
MO8U)QH1A^4O_  12_P"2H_&S_L0?#_\ ZD3UX)_P5K_Y/"UK_L0O W_I!<U]
MU?\ !)']G/XS?"G7OBOXY^)O@/7O .E:[H>B^&M$LO%EC/HNN:G>VNI3ZC?7
M$6B7J1:E!I]I$+>/[;>6]M!=S72II[7?V>\-MX[_ ,%/_P!E+X^_$+]HZP\?
M_#OX:^)?'OAKQ5X3\.Z-!>>%-/EU=M*U?11<VEW9Z[%;AI-(A:.2VNX-2OU@
MTN:*=HUO//M;J.+^BLLXDX>A])GB#,)YYE,<OJ\*T\#2Q\LPPL<%4Q=+ 9-.
MIAH8MU5AY5:<:%?G@JC<94:D':<)17\#\0^'_'57]G5P+D=+@WB>IG>&\3*V
M<XC)89'F4\XHY5B<ZXLHX?,*N5QPSQT,+7GCL'[*M*@H5*>*P]6+=*M3G+]@
M_P!C#_DTW]G?_LD?@G_TRVM?35>)_LV^"=>^&WP ^#?@+Q1##;>)/"7PX\):
M'KMK!/'=16FK6.CVL5_9K<PLT-Q]DN1);M/ [P2M$TD$DD3([>V5_&'$U:CB
M>).(,1AZD*U#$9WFU:A6IR4Z=6C5Q^(J4ZE.2NI0G"491DFU*+36C/\ 77PY
MP>*R_P />!,!CL/6PF-P/!O#&#QF%Q$)4J^&Q6&R3 T<1AZ].24J=:C6A.G4
MA)*4)QE%I-,****\0^R"BBB@ K\??^"^G_*(;]M7_L2? W_JXOAS7[!5^/O_
M  7T_P"40W[:O_8D^!O_ %<7PYH ^\/%O[9/[(O@/0;[Q/XS_:B_9Z\,>']-
MB>:\U;6OC)\/+"SB"122^6LD_B%3/<R)$_V>T@$MU<NOE6\,LI5#_*U\58F\
M9?\ !(+_ (+I?M)>"=$U7PS^S=^U'^U._P 4OV;]/U+0[[PU;^+?!\'C_P""
MWAOQ#\8M#T34+6RN[+0/BGXFTJZO].-S9V=S/_8\LT]M$67=_39I'_!.;_@G
MMH&IV6M:#^PA^QIHFL:;.MUIVK:1^S!\$=-U.PN4SLN+*_L_ \-U:SID[98)
M8Y%R<,,U\B_\%[XHH/\ @D#^VC##''###X%\!Q111(L<444?Q@^'"1QQQH B
M1H@"HB@*J@*H  % %%/@?_P6%^+_ (1G^,4G[>'@']E;XA>*+&#Q5X1_9/T'
M]F'X8?%/X4?#JUGM)K_1_AE\4?BSXTMI_BMXN\3&.33M)\?^./!<WAC2=)UE
M-:N/"/A/5M.ATY+GM_V<?VU?VG/VE/\ @G_XS^+7P^^!O@C5?VYOAMXP\>_L
M]>-_@C?>*1X=^&.D?M%_#7X@P_#KQ?>7NN:AJ[ZG9_#[1+:XC^)U_H3ZS_PD
M\_AR&X\*:1JU]K,VFZS>_JY7\G$GQP^,G[/O_!/[_@JMX_\ @MXMU/X9ZG/_
M ,%POVI_!WC[XQ:)X=A\5:W\%?A%XU_:)\&>&_B3\4='T>Y@N[9M0\.>'[^:
M.+4);*XDT=;^35[-K#4+&TU6P /TR\5?LV_\%A/"O@'5/B3X3_X*6^$?B3\:
MM$L[GQ=;? +7/V0?@QX;_9T\8:C:VLM^WPHL_$NDP?\ "]=$T6]G5=$TKQQ<
M?$"[UQ]L6H7^FVANY(K#S[]JC_@IK\7;/_@E_P#LI?MY_LS^#K9?'?QP^)7[
M+44OPFUE+#4XM?B^)'BFVT?QO\(X-9O[(FV76M5BOO".E>-+.TL-3@@EMM>M
M(K"=_L\?D?Q4^%?_  1M^%GP@M/BEKGCB]_;S^+GB#1[R'X4:=XD_:Y^*G[4
M'QU_:2^(FK64$&CZ)X0\':1\3]6T^\U7Q#J$>DVVKW7A#P3X?\*>$K!7UO5H
M-"TO3[JZB^9K+_E!#_P2&_[.E_8#_P#6BTH _5VV\&?\%%?V;O@O^U+\?_C_
M /MT^%?CM>Z/^RE\6O&_A7X2>'_V7OAS\-O"?P=^-'AOPIJ'C+2]4\%>-]-U
M2_\ %7CCP1H)T^]\.0:)\2[#5]1UVW73M<U#4;2X%[IEQ\M?LNZ3_P %F?VZ
M?V<?A%^T]K/[<OPX_8FC^)'PK\#>)_ 'PE^'_P"RQ\,?C7'XOTS4/"FD7=K\
M3_BCXG^)EP;W1)OBE?>?XQTSP3\/5TZR\)>#O$6E:;)JM[KEM<-;_K;^W-_R
M9-^V'_V:S^T'_P"JE\75Q/\ P3._Y1O_ /!/S_LR/]E+_P!41X"H _,3]FOX
M\?\ !5'_ (*%:E\1/A]8_$OX8_L(67['_P 1_$G[.?[2/Q<^'_PP\-?'7Q3\
M<?VC_ .NS_\ "4VGP6T'XKR7W@[X>_"O_A [OP1XIN-4\5^'O$OB2+5_&BZ1
MI,6HV%J^I:=]4?L<_'7]J_P!^V/\6_\ @GM^V3\0O"GQZ\5:%\#/#W[4'P#_
M &C?#?@'2?A9K/Q*^$5[XV/PU\::-\2? /ABXG\&Z'XR\%>.;C2K&WE\*QV5
MGJFCWT6JW-C;?;;2*/,_X)'_ /(=_P""K_\ VF"_:J_]5Q^S_6=XGN;ZS_X+
MQ:3>:78_VIJ5I_P1L^)MSIVF^<MO_:-]!^V1\.9;2Q\]\I!]KN$CM_.8%8_,
MWMPIH W;'X/?\%8?V@=9\:^/_%_[8NB_L%>&I_$GBS2/A1\ ?@_\"/@9\>/$
M.E^#M*UV_P!.\+>+OC'\3_BS8^.--UOQ=XDTVTMM<N/#GPWBT/P[INGZA;0O
MJ9U1[JQTKK_V,_VK?C#8VO[8_P &?VX=;\$77Q1_8'U30[SXA?'?P5HY\+>!
M?BG\&/&7PYN/BIX*^+%SX02YOQX(\31^%-.UJ'Q]X5T^XN]'TS5=*:;19VL[
MQ;:V_+']B9OV(?VSOV;+K]I?_@IA^UW/\1OC_<ZYX[NOCS\'?B[^U7XS^ GP
MV_9:UC1O&6OZ4?A7HO[-VA?$KX?Z-X)T/0--T.P6'4O&^C^(]?\ %%Y#<ZZF
MO31W<=I:[G[!/PJ^#W[2>L_\%S?@G^S=X'U/X&_ _P"/_P +?@Q\*_A'/KVD
MZ_I+ZCX4^)_[,WQ2\%Z=\8[/0_$ANO$=KX4\=W>L77C_ ,&C5H(M1U7P9J6A
M:Q+IEBVIC3X #[V\#Z+_ ,%)?VU/#&G_ !^TO]J9?^"??PJ^(.F0>(_@C\#_
M  ;\ /A-\8OB_%\/=7MX[SPAXN_:"\8_&>Q\5Z!IGCGQ5I<\/B"_^&/P^\-Z
M79^!;2^T_P .ZGXRU[7K#6;A]S2?VL_VDOV-/@/^V!XQ_P""B6BZ)XST;]D[
M1_#_ (L^'_[1WPL\/6W@GPY^U-X2\:6MQ8^%_#]KX N-<UO_ (0?XR6'CNWM
M/ WBW28;E/"2W_BKPK?Z.YTNX:_O.O\ V7/^"C?[..N?#70O 'Q\^)?P\_9@
M_:6^$^A:-X'^.OP!^-_CCPO\-?%_@OQQX;TN#3=:O?#]OXMUNQC\;?#77)K.
M37O 7Q#\,7>L>'_$GA/4-)OVO;:_EO-.M/DS]L/XEV7_  5]_8/_ ."B/P0_
M9$\,7GQ#\)_#X_#C3?AE\88K_;\./VE/BA\*?''AKXU^,?AY\)[Z"*"?6],T
MJZ\!:-X"?QK:7\7AS7]?\7VX\/:S_9MC/KB@'JW@OX*?\%>OCKX*M?B]X^_;
MM\+_ +&WCCQIIEAXE\.?LQ_#+]EWX2?%KP1\*+6^A34=.\&?%+QU\6;6]^(7
MCWQ7;6LMKIGCNX\(:SX!TNQUF/5X?#$\]HMA?)X]XL_X*3?M*>'_ /@GS_P4
M8U;QSH?@7X=?M\?\$]8[WP1\0SX9L9M?^&.OZGK.DZ%XC^%WQK\$Z%XC>>\B
M\'_$CP;K@U[1_#WB9KBZL=2T^]CU"U-@UO9GQ?X _";_ (-Z_CK\++3XBW6F
M?"KX-Z[IMF\7Q/\ A1\</VI?BI\*_B?\&O%>F/#9>*O"'Q%\)>.?C/X>UC1K
MSPUKDDNC3ZM+8IHFISPBXTJ^NK>:-JV!\"_V3?VAO^"6?_!331?^"7_P&U_P
MYHGQ/TKQQX(\-^,KN3QAJ,'[5/B/X/>$M(U.RU[X8ZAXZ\3^(?%&N^%7U>?Q
M!\,/!NI7L>C:3JGB73=3ETY)-.E:^H _HB\&ZM=:]X0\*:Y?"(7NM>&]#U:\
M$"&. 76HZ7:WEP(8V>1DB$LSB-&=RJ84NQ&3^*MK\8/VF_VM_P!EW_@K-H%G
M\:=*^$^O?L[_ +9'[57P)\#^*=+^%?A7Q<TGP+^%_P (_ 7B-? >IZ+K5Q:V
M-UJOB >+M<L+GQL\C:UI\<\%Q;1R2VT8/N_[/G_!6K_@GUXH_9-^'GQIU_\
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M)7BK2X_#/A'X@^*M'BG\,Z<]IK,D5K=>*?#\UN >R?&WX:?\%6OV6O@QXO\
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M^7?_ (.N?^1H_9C_ .O#3/\ U.KROZB/^"?_ /R9;^S9_P!DL\/_ /H$M%%
M'\1G_!Q+_P I9OA/_P!R9_/PO7]\/P,_Y(E\'?\ LEGP^_\ 42TBBB@#^&/X
MR_\ *RI!_P!EAT__ -231*_L$_8F_P"1E_;J_P"SZ_B3_P"JE^!M%% 'X5_\
M$O\ _E.!_P %'_\ L:?'/_J3ZM7]#7[)O_(I?%O_ +.E_:A_]7;XQHHH _BU
M_P""[7_*8GX,?]?O@[_TR6]?V=_M3?\ )E/QI_[('XE_]1&6BB@#^9'_ ((0
M?\WL?]FZZW_[4K]\_"/_ ";O_P $I?\ L-_L^?\ K)'Q,HHH _)?_@Y#Z?LV
>_7Q9_**OU9_X(X_\H\O@+_UX^(O_ %)-3HHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>eldn-20250806.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-08-06T14:55:58.6238+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.eledon.com/20250806" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:eldn="http://www.eledon.com/20250806" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" namespace="http://fasb.org/us-gaap/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.eledon.com/20250806/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://www.eledon.com/20250806/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="eldn-20250806.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20250806/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10091.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Aug. 06, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  06,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Eledon Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001404281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-1000967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">19800 MacArthur Blvd.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Irvine<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">238-8090<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ELDN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="eldn-20250806.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20250806/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="eldn-20250806.htm">eldn-20250806.htm</File>
    <File>eldn-20250806.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>12
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "eldn-20250806.htm": {
   "nsprefix": "eldn",
   "nsuri": "http://www.eledon.com/20250806",
   "dts": {
    "inline": {
     "local": [
      "eldn-20250806.htm"
     ]
    },
    "schema": {
     "local": [
      "eldn-20250806.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 23
   },
   "report": {
    "R1": {
     "role": "http://www.eledon.com/20250806/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_502a57ac-65d1-44e4-b1ec-0d018b37d327",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "h2",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20250806.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_502a57ac-65d1-44e4-b1ec-0d018b37d327",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "h2",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20250806.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.eledon.com/20250806/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.eledon.com/20250806/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.eledon.com/20250806/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.eledon.com/20250806/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.eledon.com/20250806/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.eledon.com/20250806/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.eledon.com/20250806/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.eledon.com/20250806/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.eledon.com/20250806/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.eledon.com/20250806/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.eledon.com/20250806/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.eledon.com/20250806/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.eledon.com/20250806/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.eledon.com/20250806/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.eledon.com/20250806/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.eledon.com/20250806/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.eledon.com/20250806/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.eledon.com/20250806/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.eledon.com/20250806/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.eledon.com/20250806/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.eledon.com/20250806/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.eledon.com/20250806/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.eledon.com/20250806/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>13
<FILENAME>0000950170-25-103975-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-103975-xbrl.zip
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M6 OZ3E.1)&)$3N*4I6',$G)1][H'PPP;Y#!)R#E6R\FYR(6\%KQ1-MHM !X
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MI%)$0@*3%_F' R3U5JXH"SHBBO1;2*#O=W)8^ 3)3+WK2AP'TA"MB:5QDW/
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MG(M3^+)2G6+NY!=?UV/EF"=G70:\+!0#);ZJK9L%N,<"2&!NEJ+J-N9AY>+
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MKF7MS]/Y-@?K*@ !F"<A1/H3^2#.!Z"1689=T=2=/!"8_F%7=TG[Y)P8IM:
M@K<2 W.5+8G+SJO 9=>W0B\"C=_T D&M  Q)ID4Z#:W M6SXYHJE#PQ<@  ,
M >CIU6=@J,!5DRTB3X1;C*%#>A5X[F.Q;C&J&Q.(/)7%9(S&%FC7JN0;Q.0P
M-$+/,##)I:ZA2\2FONM$5'-MYG/7M3Q#7Q:3SZ1 CHR))E46*A3Z\DL48<["
M+4:/<_) Z^$$F.;R:-WBU-@-WBV&WV79-XCA@<[-*-+0RV=:U#*!:P.N1]3C
MD6-88:#IH;%B#._D^4#(+9ZO",]-$+&8*'P1/*_*WL'SE:?[\M>0[FN%PO)6
M?RMM)B'!ZNK/2@*F&$IE0P%P6Z_"86<^Y9C^4Y((Z/::.K+F=_1<@8\KWZ6^
MZ]XQQNZ=38OZ6<].@3JF=HG9X,N,96&W3.R\QL"!AY>$_!BI'\W<AK)MD7UY
M9+^4#"==II8>]:#V[EHCB[:8OL7T-;+UTRJ!E^+JHM920;&"WN#-K?:UUK,,
M;_3\@F5I?NBX-+!-%PP_S:6>H=F4!X9NVIX>6.;2AE^E68]T(U 2_8D8M]A&
M"]A)@$D7119^W2/_!RNHZ004:'+-DL%;S.WS/7#1UT%)NN8$@:-1@^L1M5P>
M4-^+#.IK)O,\UQ!1M+2[NU(42AWA.<GH^-/1Z998ML3R;,3BNEH4,DY#Y@&Q
M>"!V_, -J148?F@%?F1$2Q]YK<5.[0=3>6'O^1A1_UCJ.-9"6'#*<L[^(A^3
M+& )^<SD5U$\>Q#<W%SXCZ2$EW*&=E*.CD]!@A$)52 %#/PK:(M"I6ZZ$^40
MYP2&+ "85[CQ=26S8=%%_VD?(Q]83KB(XK3,$UMNXVKVC%S^MRG\3;*+1.SN
M8S"OZ>^K'=VZ#O0&V-7'1+,81%3Z8HV &@M>#W"W;73/WE:?:+VQ2>[IJ;B,
MY[T]8Y,0\?@!I)ISZ0T.X(%]%U"S32?"ZVQ<6P.>ICO4=YA!/>YJ#M<]P["6
MCO<H#\O58_^HAMXN1_[R6RYO"G\ZT3=8TQXPI)E\+KX7R-4%+B82$1; Q=),
M[4T,<J%*P<2K<#&\>U-=;$?*6_EPJ55?R0@['\;0-2)O"A.!+U)<QSG4B\8W
MR[(PQ%RM6!CO)>5,\KP,%.,/;8R8NVR\,3+)[1J+D,CC\.DY\G9,>VMFW_>W
MP3&5W[Y*,4K$#>6Q+-<*-XP&O72_OJT4O]Z_;1$O/HVC4=VK*D4!O^9<P]@=
M^V4J")=WPE)ULV2YY37] 9HL7_?9E2C=-)1%(/9:+!FR45[MYVS6'9$+7?<V
M[^ZO9XM@??;]TDXA>L0%4P43\0^2,NCTY(C<7IY]FWMGZE*R-=EM+\7DOZ2D
MNA:FNA5FC\R^]:&\KWL7>25J?X:V7TEE]:3O(U>N/I0-5._?@8J;#X %,^#&
M>$09D%(PX/\L38%AXRXS&?3QAAQ.X#<CD<QZBB57[?^<DRR]RK <# DJZ@')
M^B*E"0M$ I(#N;] AQE3W+\05UE?#@(@7B5$L"GH&2\/J@*-,WD%@)?B/Y4@
M -7Z:\Q3,2K%$' 8$!1]: VJY V\F'R0%#D9"JE:RM%BA/D4JNG?,YEP<GE;
ML0VC51,MV%<5K)P $+&/"^CT1**XRL-LC[0/&^001%Q_'. \#1^T#(J"@6CE
M! P' 9*+H5;>C8.X(+[?T &$:!?4:5^A'(CB\07 JE*<-IY5!FTH5C]6X_\N
M)GV8Y(!6V5V"5EC"<D4#<1F*STNF)_C>)*$AQG6S7!$10RV^1B0@_P05)ZPV
M0,2&.C7)CDDR!-&(C$(1\2S,AD&67+<FRKL]#&/X%4!A& .T#"4G!C<^FCH4
M08YIN8#\\+[IO-5LQG+R"ODXO19YD4E:2C\5?P0:I<09S.AV2Q]O9=*7763#
MI0E9L?U;K:!V8+0'4F($6W4+'2H)]2F7W7A\!GJ2"[\C>1?1%TT;P%XNP&+B
MM2B,8D#,6D(BXH,A O@M5*:.L2'B+>A^V4,Z9KW29)H4Q9.%:[F[AQ(Y0Y_3
M$$PED@\"E'<U%20Q4[%8<3F4H@OTE)?CV8.IR&I2,<Y)M32>VMXW1 Z %!E)
M>;PG?_BX0>6J>G ^T\5O9S1($U$QH)IIY>5-2DC*(Z)25N7E;(J[RYWCW /%
M '(P"N4#J_1 2"* 8&+>N8+,]-110-<GFQZ>^?VFISC05DWO$1\)\F1LV:M$
M91A6FBM15M%>_C;U=;S*M8; 6V3BY)O1JY-G6I6%OK)PUJF@=E5OV1/IYA-B
M2#UWXV-(RW<+;/Y-5ZX3HJB7+[!O^KR!1+6^<)HUEM];W4)XYGU8>2CCOKH0
MY>6S"6R8KW7+*+>,<MUDO%B"(["?M@Q1TZ)H64B>U6!DI"MQYU4D/*7BQO?_
MU!O=HO?XOM7HN0BK&Z5:RJ3!_8\J(GCQL2FWYGGEUNR4WF PR.:$"#QQ7*2N
M_ C'V92_;(R/;,-">5\_FB_/,'3-VO*+U40>P_S)&;L"BL0 .!:J1+%'N .C
MKC?;%;U <'3,X-Y[7#IC.VH#E/SQR_DGPK-P@%;Y-H7G=F_[A?>V5XQ:52JG
M5W08N//Q]/#RM_/CBV=T"=V'RB;YA<XF GS*^*._!D!AI=MP4>_ZC, E/DA&
M)&0###92&P2RW!@H7<DY@*%49F+H)A!=ED3H%E8[9*B75 5P*W: #F+5'-!7
M-Y,  -[XII&V*6>QG:><=K:>4NDI=>:/[J45M^T)@BW0MD![NT"S&N:C-NS*
M\NNT!F:'?*FLW[,=ULOFRMVRT>\%N;= VP)M"[0-<A-NG#A;KV/K" R>UBO
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M4(<2!$=/"PCXAV]W@U5=0/?,1X+)_$GG!70Y?LN?/6Q_P9[C/0U8370N*#2
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M0\/$A:$!.SI;)+0$T&D5A3J$G,"8G9"XY#C5EPC6U$G6='=='.YO:>1;T$A
M:)TT]!0'G)SR6E.Z[;NV^VNS3ROII=YP#//5"[1UYOD F\ZC>!AH.MAB0$^'
M9=:PS,]QXG E74AI2#U>E'O@%ST5!W<EC\CFWM>D$?_F;%&%M*DM=U3L5\=D
MM7L01S;C5/%P^0& [KY.Y$1Y(^B62X_)=B##N5RDVZSP-BO\O^ QG<6"Z-;Y
M)DDC$R%'(/J99@U:9278F*H#'VD^F9">90G_M7F&MCA>68)R'N0#$U)4(_.1
MR%B%(E S%9K$N4WL@TD+-[T1SWH)TSMIP8CPC85)P I^-13""K_E0BDZAG:2
MN]>F4<1.8&+8(BE<=CW& ^FB>+!H=K$I*R,%@9"2&6HH; (XA!1],Q/8+%#[
M(L5&5%L\8UL&BS,(?7(D?1<W*KS2-5CSBZF+YGG]]N'^EUF\=!!OK]WMEL-I
M7!73J >N!!S$6,X KA','CZ(UVL_/FJ:<6Q0D1^ST5:#\7<L CTNH_!XMOE
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-  , NP   +TR      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>eldn-20250806_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="eldn-20250806.xsd" xlink:type="simple"/>
    <context id="C_502a57ac-65d1-44e4-b1ec-0d018b37d327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
        </entity>
        <period>
            <startDate>2025-08-06</startDate>
            <endDate>2025-08-06</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_502a57ac-65d1-44e4-b1ec-0d018b37d327"
      id="F_5ec0ef4e-0516-4dab-aa73-5e9c894bfd03">0001404281</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_502a57ac-65d1-44e4-b1ec-0d018b37d327"
      id="F_841276ef-13f2-48a3-9a50-b6d065e32840">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_502a57ac-65d1-44e4-b1ec-0d018b37d327"
      id="F_81894906-6b70-4329-a58f-a72c9467864a">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_502a57ac-65d1-44e4-b1ec-0d018b37d327"
      id="F_2505cf70-d722-4473-81a4-a1d3e427db33">2025-08-06</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_502a57ac-65d1-44e4-b1ec-0d018b37d327"
      id="F_0be36927-077a-4904-97e7-c071dc3dfd6d">Eledon Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_502a57ac-65d1-44e4-b1ec-0d018b37d327"
      id="F_47304ba4-b9c8-40d8-8a91-8c54beadc4d3">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_502a57ac-65d1-44e4-b1ec-0d018b37d327"
      id="F_fe0a2b56-3c7a-4e46-b91a-043aed291c7a">001-36620</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_502a57ac-65d1-44e4-b1ec-0d018b37d327"
      id="F_820d975b-3a16-4db3-b294-fec4f88c9c8e">20-1000967</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_502a57ac-65d1-44e4-b1ec-0d018b37d327"
      id="F_517366ec-31ce-4923-b15c-acc9c96ca850">19800 MacArthur Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_502a57ac-65d1-44e4-b1ec-0d018b37d327"
      id="F_e783693c-fb81-4bc4-bc26-68c47e0e9956">Suite 250</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_502a57ac-65d1-44e4-b1ec-0d018b37d327"
      id="F_66e10d00-6ebd-44e5-a9bf-e30d6d45796f">Irvine</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_502a57ac-65d1-44e4-b1ec-0d018b37d327"
      id="F_74922468-c6cf-40d9-a3c3-cb79ae39f180">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_502a57ac-65d1-44e4-b1ec-0d018b37d327"
      id="F_86d36c5c-c22e-4443-b15f-9756c50e90c4">92612</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_502a57ac-65d1-44e4-b1ec-0d018b37d327"
      id="F_9f589433-a284-4d99-b932-5c082f8dab7f">949</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_502a57ac-65d1-44e4-b1ec-0d018b37d327"
      id="F_8f8d79e0-dc68-44cd-b331-d74316323a43">238-8090</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_502a57ac-65d1-44e4-b1ec-0d018b37d327"
      id="F_e68fa96c-ebc7-4457-a152-ecb22ed2ca85">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_502a57ac-65d1-44e4-b1ec-0d018b37d327"
      id="F_794c8f38-38be-4b99-a0f1-c4b7454c87ee">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_502a57ac-65d1-44e4-b1ec-0d018b37d327"
      id="F_cc2c8223-9a10-4d95-976f-075a9d774821">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_502a57ac-65d1-44e4-b1ec-0d018b37d327"
      id="F_b1d3ff02-5c34-4338-9a1f-8df624cb01c2">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_502a57ac-65d1-44e4-b1ec-0d018b37d327"
      id="F_64409c67-b537-4307-8205-db213581b432">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_502a57ac-65d1-44e4-b1ec-0d018b37d327"
      id="F_6106bb60-2d1f-47db-98f2-903a8872effe">ELDN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_502a57ac-65d1-44e4-b1ec-0d018b37d327"
      id="F_6770fcad-ca8f-4807-9b7c-4b29c4b9f2f6">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_502a57ac-65d1-44e4-b1ec-0d018b37d327"
      id="F_db236f29-a750-4416-96a2-8d706d182245">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
